Compositions and Methods of Use for Therapeutic Low Density Lipoprotein-related protein 6 (LRP6) Antibodies
AssigneeNovartis AG
InventorsFeng CONG, Seth ETTENBERG, Felix HARTLEPP, Ingo Markus KLAGGE
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies targeting LRP6 and compositions and methods of use thereof.
Claims27
1-11. (canceled)
The antibody or fragment of claim 61, wherein said antibody or fragment is a monoclonal antibody.
The antibody or fragment of claim 61, wherein said antibody is a human or humanized antibody.
The antibody or fragment of claim 61, wherein said antibody or fragment is a chimeric antibody.
The antibody or fragment of claim 61, wherein said antibody or fragment comprises a human heavy chain constant region and a human light chain constant region.
The antibody or fragment of claim 61, wherein said antibody or fragment is a single chain antibody.
The antibody or fragment of claim 61, wherein said antibody is a Fab fragment.
The antibody or fragment of claim 61, wherein said antibody or fragment is a scFv.
The antibody or fragment of claim 61, wherein said antibody or fragment binds to both human LRP6 and cynomologus LRP6.
The antibody or fragment of claim 61, wherein said antibody or fragment is an IgG isotype.
20-48. (canceled)
An isolated antibody or fragment thereof that binds to a low density lipoprotein-related 6 (LRP6) or fragment thereof wherein the antibody or fragment thereof comprises a VH comprising SEQ ID NO:
- 82 and a VL comprising SEQ ID NO:
- 81, wherein the antibody or fragment thereof is monovalent or bivalent.
An isolated antibody or fragment thereof to LRP6 that binds to a low density lipoprotein-related 6 (LRP6) or fragment thereof wherein the antibody or fragment thereof comprises a VH comprising SEQ ID NO:
- 90 and a VL comprising SEQ ID NO:
- 89, wherein the antibody or fragment thereof is monovalent or bivalent.
51-60. (canceled)
An isolated antibody or fragment thereof that binds to a low density lipoprotein-related 6 (LRP6) or fragment thereof wherein the antibody or fragment thereof comprises a heavy chain variable region CDR1 of SEQ ID NO:
- 69;
- a heavy chain variable region CDR2 of SEQ ID NO:
- 70;
- a heavy chain variable region CDR3 of SEQ ID NO:
- 71;
- a light chain variable region CDR1 of SEQ ID NO:
- 72;
- a light chain variable region CDR2 of SEQ ID NO:
- 73;
- and a light chain variable region CDR3 of SEQ ID NO:
- 74, wherein the antibody or fragment thereof is monovalent or bivalent.
62-65. (canceled)
68-72. (canceled)
(canceled)
76-85. (canceled)
87-98. (canceled)
100-108. (canceled)
Dependencies are inferred from the claim text.